Otilonium Bromide: High-Purity Antimuscarinic Agent for Neuroscience Research

Executive Summary: Otilonium Bromide (C₂₉H₄₃BrN₂O₄, MW 563.57) is a high-purity, solid antimuscarinic agent that functions as an acetylcholine receptor (AChR) inhibitor, supporting robust studies in cholinergic signaling pathway modulation (APExBIO, product page). Its solubility profile (≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, ≥91 mg/mL in ethanol) enables versatile assay development. The compound is validated for research on smooth muscle spasm and gastrointestinal motility disorder models, with evidence-backed specificity for muscarinic receptor antagonism (Journal of Proteins and Proteomics, DOI). APExBIO supplies this SKU B1607 with ≥98% purity, and short-term solution stability is optimal at -20°C.

Biological Rationale

Otilonium Bromide is categorized as an antimuscarinic agent targeting muscarinic acetylcholine receptors (mAChRs) in neuronal and smooth muscle tissues. By inhibiting AChRs, it disrupts cholinergic neurotransmission, which is essential for modulating smooth muscle tone and motility (see review; this article extends mechanistic clarity by detailing solvent compatibility and storage parameters). The compound is especially valuable in experimental models of gastrointestinal (GI) motility disorders, where excessive cholinergic signaling causes spasmodic contractions. Its high purity (≥98%) ensures minimal off-target effects in receptor modulation studies. Otilonium Bromide is not indicated for clinical or diagnostic use but is strictly intended for scientific research, as per APExBIO guidelines (product page).

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as a competitive antagonist at muscarinic acetylcholine receptors (primarily M2 and M3 subtypes). By binding to these receptors, it blocks acetylcholine-induced calcium influx and subsequent smooth muscle contraction (DOI). In neuroscience research, this mechanism allows precise modulation of cholinergic signaling, facilitating studies of synaptic plasticity, neurotransmitter release, and smooth muscle electrophysiology. The selectivity for mAChRs over nicotinic receptors is supported by in vitro pharmacology and functional assays. The compound's efficacy is retained in aqueous, DMSO, or ethanol-based buffers, permitting integration into diverse experimental workflows. For a comparative scenario-driven analysis of similar agents, see this article, which this dossier updates by incorporating new solubility data and workflow guidance.

Evidence & Benchmarks

• Otilonium Bromide achieves ≥98% purity by HPLC, supporting reproducible receptor inhibition studies (APExBIO).
• Inhibits muscarinic AChR-mediated smooth muscle contraction in vitro at concentrations as low as 1–10 μM, under physiological pH and 37°C conditions (Journal of Proteins and Proteomics 2021).
• Solubility benchmarks: ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, ≥91 mg/mL in ethanol at 25°C, allowing compatibility with most standard assay buffers (APExBIO).
• Recommended storage at -20°C preserves compound stability and efficacy for at least 6 months (APExBIO, product page).
• Validated for use in cell viability, proliferation, and cytotoxicity assays where muscarinic receptor modulation is required (see protocol guidance; this dossier clarifies solvent and concentration selection).

Applications, Limits & Misconceptions

Otilonium Bromide is primarily used in neuroscience and smooth muscle research to study cholinergic signaling, receptor pharmacology, and GI motility models. Its high selectivity for muscarinic receptors, coupled with excellent solubility, enables broad application in bench research. The compound is not suitable for clinical or diagnostic purposes. For a discussion of advanced receptor modulation protocols, see this review, which this article extends by providing updated purity and storage parameters.

Common Pitfalls or Misconceptions

• Otilonium Bromide does not inhibit nicotinic acetylcholine receptors; it is selective for muscarinic subtypes (M2, M3).
• It is not intended for any therapeutic, diagnostic, or in vivo medical application—strictly for laboratory research use (APExBIO).
• Long-term solutions (>7 days) may degrade even at -20°C; fresh preparation is recommended for each experiment.
• It should not be used as a reference for antiviral or unrelated signaling pathways (e.g., NSP15 inhibition in SARS-CoV-2 is not a documented mechanism).
• Solubility in organic solvents does not guarantee stability in all biological matrices; empirical validation is required for each assay.

Workflow Integration & Parameters

APExBIO's Otilonium Bromide (SKU B1607) is supplied as a high-purity solid, facilitating precise weighing and dissolution. Solutions can be prepared in DMSO, water, or ethanol to achieve target concentrations matching assay requirements. Optimal working concentrations range from 1 to 100 μM for most in vitro and ex vivo applications. For cell-based assays, a 10 mM stock in DMSO is recommended, diluted into culture media immediately before use. Stability is maximized by storing aliquots at -20°C and limiting freeze-thaw cycles. For troubleshooting workflow compatibility, see this integration guide, which is expanded here with quantitative solubility and stability data.

Conclusion & Outlook

Otilonium Bromide, supplied by APExBIO, is a validated antimuscarinic agent and acetylcholine receptor inhibitor supporting advanced neuroscience and smooth muscle research. Its robust solubility, purity, and specificity underpin reproducibility in receptor modulation studies. Researchers should integrate empirical controls and adhere to storage guidelines for optimal results. Future work may involve high-content screening or combinatorial studies to further dissect muscarinic signaling in health and disease models. For full product specifications, visit the Otilonium Bromide product page.